3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
45
Lymphoma, Mantle-Cell
22
Waldenstrom Macroglobulinemia
12
Lymphoma, Non-Hodgkin
10
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Follicular
10
Lymphoma, B-Cell
10
Leukemia
10
Recurrence
7
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Neoplasms
4
Hodgkin Disease
4
Leukemia, Prolymphocytic
3
Leukemia, Lymphoid
3
Leukemia, B-Cell
3
Chromosome 17 deletion
3
Burkitt Lymphoma
3
Bronchiolitis Obliterans Syndrome
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Leukemia, Hairy Cell
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Interventions
blinatumomab
9
Cyclophosphamide
7
Rituximab
6
Lenalidomide
6
Dexamethasone
5
Azacitidine
5
venetoclax
4
fludarabine
4
Cytarabine
4
fludarabine phosphate
3
Maintenance
3
Busulfan
3
tislelizumab
2
thymoglobulin
2
pembrolizumab
2
obinutuzumab
2
daratumumab
2
Whole-Body Irradiation
2
N,N-dicyclohexyl-isoborneol-10-sulfonamide
2
Methotrexate
2
Melphalan
2
Immunotherapy
2
Imatinib Mesylate
2
Drug Therapy
2
Docetaxel
2
Decitabine
2
Clofarabine
2
Cladribine
2
Carboplatin
2
Calcium Dobesilate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm, Residual
×
ibrutinib
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled